Related Experiment Video
Updated: Apr 23, 2026
09:35
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
14.3K
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice
Jacqueline M Langdon1, Sangjucta Barkataki, Alan E Berger
1Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
American Journal of Hematology
|September 20, 2014
Summary
RAP-011, a sotatercept ortholog, effectively increased hemoglobin in mice with high hepcidin antimicrobial peptide levels. Unlike erythropoietin, RAP-011 did not deplete iron stores, suggesting it may treat anemias with iron-restricted erythropoiesis.
Area of Science:
- Hematology
- Pharmacology
- Molecular Biology
Background:
- Hepcidin antimicrobial peptide (HAMP) overexpression is common in iron-restricted anemias.
- Sotatercept, a ligand trap for activin receptor type IIA, targets TGF-β superfamily signaling and is being evaluated for various anemias.
- Understanding treatments for HAMP-related anemias is crucial.
Purpose of the Study:
- To investigate the erythroid response to erythropoietin (EPO) and RAP-011 (sotatercept ortholog) in mice with normal and HAMP-overexpressing conditions.
- To compare the effects of EPO and RAP-011 on hemoglobin levels, splenic iron stores, and erythropoiesis.
Main Methods:
- Administered EPO or RAP-011 to C57BL/6 and HAMP-overexpressing mice.
- Measured hemoglobin concentration, splenic iron content, and transferrin receptor expression on bone marrow erythroid progenitors via flow cytometry.
Main Results:
- Both EPO and RAP-011 increased hemoglobin in both mouse models.
- EPO treatment depleted splenic iron stores and induced iron-restricted erythropoiesis.
- RAP-011 treatment did not deplete splenic iron stores and showed less iron-restricted erythropoiesis.
Conclusions:
- RAP-011 improves hemoglobin levels in HAMP-overexpressing mice.
- RAP-011 exhibits unique effects that prevent splenic iron depletion, unlike EPO.
- RAP-011 shows potential as a therapeutic for human anemias with high HAMP and iron-restricted erythropoiesis.
